Skip to main content
Delfa

Lead sponsor

Amgen

29 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.

29

Trials led

17

Ongoing

30,987

Total enrollment

1,499

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
15
Phase 2
3
Phase 3
10
Not applicable
1

Trials by status

Not yet recruiting
2
Recruiting
8
Active, not recruiting
7
Completed
12

Trials led

MARITIME-CVBMI ≥27Ph 3Recruiting12,800
MARITIME-HFBMI ≥30Ph 3Recruiting5,056
MARITIME-1BMI ≥30Ph 3Active, not recruiting3,853
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)-Ph 3Not yet recruiting3,200
MARITIME-2BMI ≥27Ph 3Active, not recruiting1,105
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)-Ph 3Not yet recruiting950
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusBMI ≥30Ph 2Completed592
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)BMI 23-50Ph 2Active, not recruiting409
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsBMI 25-40Ph 1Active, not recruiting349
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsBMI 25-40Ph 1Active, not recruiting348
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)BMI ≥25Ph 3Recruiting300
MARITIME-3-JBMI ≥35Ph 3Active, not recruiting279
MARITIME-OSA-1BMI ≥27Ph 3Recruiting250
MARITIME-OSA-2-Ph 3Recruiting250
COSMOS-DIGITAL-not applicableCompleted200
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightBMI 27-40Ph 2Recruiting180
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityBMI 25-40Ph 1Completed154
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityBMI ≥27Ph 1Completed120
Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityBMI 30-40Ph 1Completed110
Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityBMI 25-35Ph 1Active, not recruiting81
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityBMI ≥25Ph 1Completed59
The Effect of AMG 133 on Gastric EmptyingBMI 27-40Ph 1Completed57
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusBMI 25-45Ph 1Recruiting56
Multiple Ascending Dose Study of AMG 598 in Adults With ObesityBMI ≥30Ph 1Completed50
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityBMI 25-35Ph 1Recruiting45
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyBMI ≥22Ph 1Completed44
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic FunctionBMI ≥22Ph 1Completed36
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian ParticipantsBMI 18-30Ph 1Completed34
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightBMI 24-40Ph 1Completed20